8-K: Regen Biopharma Secures $250,000 Funding via Promissory Note with Coventry Enterprises

Regen Biopharma has entered into a securities purchase agreement with Coventry Enterprises, securing $250,000 through a promissory note, with a portion of the funds used to repay existing debt.

Summary

• Regen Biopharma entered into a securities purchase agreement with Coventry Enterprises on September 4, 2024.
• Coventry purchased a 10% unsecured promissory note for a principal amount of $250,000, with $25,000 retained by Coventry as an original issue discount.
• The note carries a guaranteed interest of 10% per annum, totaling $25,000 over the ten-month term.
• The principal and guaranteed interest are payable in ten equal monthly installments of $27,500, starting November 4, 2024, and ending September 4, 2025.
• Upon an event of default, the note can be converted into common stock at 90% of the lowest per-share trading price for the 20 trading days preceding the conversion date.
• $152,000 of the proceeds were used to repay outstanding debt and interest to Coventry from a previous $175,000 note issued on September 12, 2023.
• Regen Biopharma issued 500,000 common shares to Coventry as a commitment, with 350,000 shares to be returned if the note is satisfied without default.

Sentiment

Score: 5

Explanation: The document indicates a necessary but potentially risky financing event. The high interest rate and potential for dilution are concerning, but the company has secured needed capital.

Positives

• The company has secured additional funding of $250,000.
• The company has refinanced $152,000 of existing debt.
• The company has a clear repayment schedule for the loan.

Negatives

• The company is paying a high interest rate of 10% per annum.
• The company has given up 500,000 shares as part of the deal.
• The note can be converted into common stock upon default, potentially diluting existing shareholders.

Risks

• The company may default on the note, leading to conversion of the debt into equity at a potentially unfavorable price.
• The company is using a significant portion of the new funds to repay existing debt.
• The company is paying a high interest rate on the loan.

Future Outlook

The company is obligated to make monthly payments until September 4, 2025, and may need to issue additional shares if the note is converted due to a default.

Industry Context

This type of financing is common for small, emerging growth companies that may not have access to traditional bank loans. The high interest rate and potential for equity dilution reflect the higher risk associated with these types of investments.

Comparison to Industry Standards

• The 10% interest rate on the promissory note is relatively high, which is typical for unsecured debt from smaller companies.
• The conversion feature upon default is a common clause in these types of agreements, providing the lender with a potential upside if the company performs poorly.
• The use of proceeds to repay existing debt is not uncommon, but it does reduce the amount of capital available for growth initiatives.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted to equity.
• Creditors may be impacted by the repayment of the previous debt.
• Employees may be impacted by the company's financial stability.

Next Steps

• Regen Biopharma will make monthly payments of $27,500 to Coventry Enterprises.
• Regen Biopharma will need to manage its finances to avoid defaulting on the note.
• Coventry Enterprises will monitor Regen Biopharma's performance and may convert the note to equity if a default occurs.

Key Dates

Keywords

promissory note, securities purchase agreement, debt financing, convertible note, Regen Biopharma, Coventry Enterprises, common stock, interest rate, default, capital raise